Brigatinib/Brigatinib vs. Alectinib: The debate over which one is better for ALK-positive non-small cell lung cancer

In the treatment options for anaplastic lymphoma kinase (ALK) rearrangement-positive (ALK-p) advanced non-small cell lung cancer (NSCLC) with central nervous system (CNS) metastasis, Brigatinib/Brigatinib and Alectinib both occupy an important position. Although both are currently targeted drugs for the treatment of non-small cell lung cancer, which drug to choose has become a difficult problem for doctors and patients. At present, there is a lack of head-to-head trials directly comparing the efficacy of the two, but there are many research records of their application in their respective fields.

Brigatinib is an ALK inhibitor approved by the U.S. Food and Drug Administration (FDA), especially for patients who are ineffective or resistant to treatment with the first-generation ALK inhibitor crizotinib. As a second-generation ALK inhibitor, it mainly blocks the growth and spread of tumor cells by inhibiting the activity of ALK protein. For patients who develop resistance mutations on alectinib treatment, brigatinib may be an alternative worth considering.

Alectinib is also an important weapon in the treatment ofALK-positive non-small cell lung cancer, and it performs well in first-line treatment. By tightly binding to the ALK protein in the body, aletinib can effectively inhibit the proliferation and survival of tumor cells, bringing hope to many patients. Its remarkable efficacy and good tolerability in first-line treatment make alectinib the drug of choice for many patients.

Although there is currently a lack of head-to-head trials directly comparing brigatinib and alectinib, an ongoing phase III study is trying to answer this question. This study will compare the efficacy and safety of the two in patients with relapsed cancer during treatment with crizotinib, providing us with deeper insights.

In cases where ALK inhibitor treatment is ineffective, brigatinib has shown its unique advantages. A phase III study of advanced non-small cell lung cancer refractory to ALK-p and ALK inhibitors showed that progression-free survival (PFS) of patients treated with brigatinib was significantly longer than that of patients treated with crizotinib. In addition, brigatinib is also relatively well tolerated, allowing patients to continue receiving treatment, thereby prolonging survival.

In summary, brigatinib and alectinib have their own merits in the treatment ofALK-positive non-small cell lung cancer. Which drug to choose should be comprehensively considered based on the patient's specific conditions, including disease progression stage, previous treatment history, genetic mutations, drug tolerance and other factors.